BRD4 and metabolic dysfunction-associated steatotic liver disease: For the 29 NAFLD related targets, the network results demonstrated that peroxisome proliferator-activated receptor alpha (PPARα) had the largest number (3) of compound connections (campesterol, Gypenoside XII, and Gypenoside XL), followed by BRD4 (Gypenoside XL and quercetin) and SOX9 (Gypenoside XL and Rhamnazin).